Guggenheim Capital LLC Biocryst Pharmaceuticals Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 14,790 shares of BCRX stock, worth $115,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,790

Previous 15,855 6.72%

Holding current value

$115,066

Previous $97,000 15.46%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$6.41 - $8.69 $6,826 - $9,254	-1,065 Reduced 6.72%	14,790 $112,000
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $140 - $230	34 Added 0.21%	15,855 $97,000
Q1 2024 May 14, 2024	SELL	$4.89 - $7.65 $1,075 - $1,683	-220 Reduced 1.37%	15,821 $80,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $529,279 - $719,522	-106,281 Reduced 86.89%	16,041 $96,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $58,819 - $69,426	8,766 Added 7.72%	122,322 $866,000
Q2 2023 Aug 11, 2023	SELL	$6.96 - $8.81 $104,462 - $132,229	-15,009 Reduced 11.67%	113,556 $799,000
Q1 2023 May 10, 2023	SELL	$7.94 - $11.84 $77,486 - $115,546	-9,759 Reduced 7.06%	128,565 $1.07 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $349,912 - $473,215	33,325 Added 31.74%	138,324 $1.59 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $266,771 - $366,162	-24,724 Reduced 19.06%	104,999 $1.32 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $139,597 - $316,350	17,693 Added 15.79%	129,723 $1.37 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $151,031 - $258,164	-13,065 Reduced 10.44%	112,030 $1.82 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $1.25 Million - $1.72 Million	111,531 Added 822.26%	125,095 $1.73 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $192,744 - $239,404	13,564 New	13,564 $195,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Biocryst Pharmaceuticals Inc Transaction History